Publications

Add filters (0)

856 results

Blood and urine biomarkers in osteoarthritis – an update on cartilage associated type II collagen and aggrecan markers.

January 1, 2022

Curr Opin Rheumatol

Abstract PURPOSE OF REVIEW Osteoarthritis (OA) is a painful disease for which drug development has proven difficult. One major reason for this is the heterogeneity of the disease and the current lack of operationalized means to distinguish various disease endotypes (molecular subtypes). Biomarkers measured in blood or urine, reflecting joint tissue turnover, have been developed […]

Read publication

Butyrate Protects against Diet-Induced NASH and Liver Fibrosis and Suppresses Specific Non-Canonical TGF-β Signaling Pathways in Human Hepatic Stellate Cells.

December 20, 2021

Biomedicines

Abstract In obesity-associated non-alcoholic steatohepatitis (NASH), persistent hepatocellular damage and inflammation are key drivers of fibrosis, which is the main determinant of NASH-associated mortality. The short-chain fatty acid butyrate can exert metabolic improvements and anti-inflammatory activities in NASH. However, its effects on NASH-associated liver fibrosis remain unclear. Putative antifibrotic effects of butyrate were studied in […]

Read publication

The activation fragment of PAR2 is elevated in serum from patients with rheumatoid arthritis and reduced in response to anti-IL6R treatment.

December 20, 2021

Sci Rep

Abstract Osteoarthritis (OA) and rheumatoid arthritis (RA) are serious and painful diseases. Protease-activated receptor 2 (PAR2) is involved in the pathology of both OA and RA including roles in synovial hyperplasia, cartilage destruction, osteophyogenesis and pain. PAR2 is activated via cleavage of its N-terminus by serine proteases. In this study a competitive ELISA assay was […]

Read publication

Safety, tolerability and pharmacokinetic characterisation of DACRA KBP-042 in healthy male subjects.

December 1, 2021

Br J Clin Pharmacol

Abstract There is a need for antidiabetic agents successfully targeting insulin sensitivity and treating obesity control at the same time. The aim of this first-in-human study was (a) to evaluate safety and tolerability, (b) to evaluate pharmacokinetics and (c) to assess indications of receptor engagement of single ascending doses of KBP-042, a dual amylin and […]

Read publication

COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy.

December 1, 2021

Eur Respir J

Abstract BACKGROUND Asthma is a heterogeneous syndrome substantiating the urgent requirement for endotype-specific biomarkers. Dysbalance of fibrosis and fibrolysis in asthmatic lung tissue leads to reduced levels of the inflammation-protective collagen 4 (COL4A3). OBJECTIVE To delineate the degradation of COL4A3 in allergic airway inflammation and evaluate the resultant product as a biomarker for anti-IgE therapy […]

Read publication

Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure.

December 1, 2021

JHEP Rep

Abstract BACKGROUND & AIMS Acute-on-chronic liver failure (ACLF) is characterised by organ failure(s), high short-term mortality, and, pathophysiologically, deranged inflammatory responses. The extracellular matrix (ECM) is critically involved in regulating the inflammatory response. This study aimed to determine alterations in biomarkers of ECM turnover in ACLF and their association with inflammation, organ failures, and mortality. […]

Read publication

Neuropathic pain in the IMI-APPROACH knee osteoarthritis cohort: prevalence and phenotyping.

December 1, 2021

RMD Open

Abstract OBJECTIVES Osteoarthritis (OA) patients with a neuropathic pain (NP) component may represent a specific phenotype. This study compares joint damage, pain and functional disability between knee OA patients with a likely NP component, and those without a likely NP component. METHODS Baseline data from the Innovative Medicines Initiative Applied Public-Private Research enabling OsteoArthritis Clinical […]

Read publication

A serological type II collagen neoepitope biomarker reflects cartilage breakdown in patients with osteoarthritis.

December 1, 2021

Osteoarthr Cartil Open

Abstract OBJECTIVES There is an unmet medical need for biomarkers in OA which can be applied in clinical drug development trials. The present study describes the development of a specific and robust assay measuring type II collagen degradation (T2CM) and discusses its potential as a noninvasive translational biomarker. METHODS A type II collagen specific neoepitope […]

Read publication

Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.

December 1, 2021

J Hepatol

Abstract BACKGROUND & AIMS The development of accurate non-invasive tests to detect and measure the extent of fibrosis and disease activity in patients with non-alcoholic steatohepatitis (NASH) – the progressive phenotype of non-alcoholic fatty liver disease (NAFLD) – is of great clinical importance. Herein, we aimed to validate the performance of PRO-C3 and ADAPT for […]

Read publication